Treatment of mild traumatic brain injury
AssigneeOxeia Biopharmaceuticals, Inc.
InventorsVishal Bansal, Kartik Shah, Michael Wyand
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for mitigating one or more debilitating symptoms of a mTBI for a patient diagnosed with mTBI, e.g. sustained mTBI. These methods comprise administering an effective amount of ghrelin or a variant thereof over multiple consecutive days after the diagnosis of a mTBI, e.g. sustained mTBI.
Claims58
A method for mitigating one or more symptoms of a mild traumatic brain injury (mTBI) for a patient diagnosed with a sustained mTBI which method comprises administering to the patient an effective amount of ghrelin or a variant thereof over multiple consecutive days after diagnosis, wherein the one or more symptoms are improved by at least 20% compared to baseline within about 40 days after initial administration of ghrelin or a variant thereof.
A method for mitigating one or more symptoms of a mild traumatic brain injury (mTBI) comprising:
- a. selecting a patient having mTBI due to an injury and the one or more symptoms of mTBI at least 7 days after the injury;
- b. administering ghrelin or a variant thereof to the patient for a period of time, wherein ghrelin or the variant thereof is administered at a dose of about 80 μg/kg per day;
- wherein the one or more symptoms are improved by at least 20% compared to baseline within about 40 days after initial administration of ghrelin or a variant thereof.
A method for treating a concussive event in a human subject by reducing the severity of or eliminating multiple symptoms associated with the concussive event, the method comprising administering ghrelin or a variant thereof daily to the subject for a first period of time beginning at least 3 days after the concussive event, wherein the severity of multiple symptoms in the subject is reduced within 45 days after termination of administration of ghrelin or variant thereof.
A method for accelerating the recovery from a concussive event in a human subject by reducing the severity of or eliminating multiple symptoms associated with the concussive event, the method comprising initiating daily administration of ghrelin or a variant thereof to the patient at least 3 days but not later than 30 days after the concussive event and maintaining the daily administration for at least 10 days, wherein multiple symptoms associated with the concussive event are reduced in the subject.
A method for accelerating recovery of one or more neuronal functions in a human subject after a concussive event, the method comprising initiating daily administration of ghrelin or a variant thereof to the subject at least 3 days but not later than 30 days after the concussive event and maintaining the daily administration for at least 10 days whereupon one or more neuronal functions are restored in the subject.
Dependencies are inferred from the claim text.